1842TiP Phase II randomized trial of two dose levels of vobramitamab duocarmazine in participants with metastatic castration resistant prostate cancer (mCRPC; TAMARACK)

de Bono, J.S., Sandhu, S.K., Fizazi, K. · Annals of Oncology · 2023